PT  - JOURNAL ARTICLE
AU  - Galbraith, Matthew D.
AU  - Kinning, Kohl T.
AU  - Sullivan, Kelly D.
AU  - Baxter, Ryan
AU  - Araya, Paula
AU  - Jordan, Kimberly R.
AU  - Russell, Seth
AU  - Smith, Keith P.
AU  - Granrath, Ross E.
AU  - Shaw, Jessica
AU  - Dzieciatkowska, Monika
AU  - Ghosh, Tusharkanti
AU  - Monte, Andrew A.
AU  - D’Alessandro, Angelo
AU  - Hansen, Kirk C.
AU  - Bennett, Tellen D.
AU  - Hsieh, Elena W.Y.
AU  - Espinosa, Joaquin M.
TI  - Seroconversion stages COVID19 into distinct pathophysiological states
AID  - 10.1101/2020.12.05.20244442
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.05.20244442
4099  - http://medrxiv.org/content/early/2020/12/07/2020.12.05.20244442.short
4100  - http://medrxiv.org/content/early/2020/12/07/2020.12.05.20244442.full
AB  - COVID19 is a heterogeneous medical condition involving a suite of underlying pathophysiological processes including hyperinflammation, endothelial damage, thrombotic microangiopathy, and end-organ damage. Limited knowledge about the molecular mechanisms driving these processes and lack of staging biomarkers hamper the ability to stratify patients for targeted therapeutics. We report here the results of a cross-sectional multi-omics analysis of hospitalized COVID19 patients revealing that seroconversion status associates with distinct underlying pathophysiological states. Seronegative COVID19 patients harbor hyperactive T cells and NK cells, high levels of IFN alpha, gamma and lambda ligands, markers of systemic complement activation, neutropenia, lymphopenia and thrombocytopenia. In seropositive patients, all of these processes are attenuated, observing instead increases in B cell subsets, emergency hematopoiesis, increased markers of platelet activation, and hypoalbuminemia. We propose that seroconversion status could potentially be used as a biosignature to stratify patients for therapeutic intervention and to inform analysis of clinical trial results in heterogenous patient populations.Competing Interest StatementKDS and JME are co-inventors on two patents related to JAK inhibition in COVID19: U.S. Provisional Patent Application Serial No. 62/992,855 entitled JAK1 Inhibition For Modulation Of Overdrive Anti-Viral Response To COVID-19; U.S. Provisional Patent Application Serial No. 62/993,749 entitled Compounds and Methods for Inhibition or Modulation of Viral Hypercytokinemia. JME serves in the COVID Development Advisory Board for Elly Lilly, manufacturer of Baricitinib, and has provided consulting services to Gilead Sciences Inc, manufacturer of Remdesivir.Funding StatementThis work was supported by NIH grants R01AI150305, 3R01AI150305-01S1, UL1TR002535, 3UL1TR002535-03S2, R01HL146442, R01HL149714, R01HL148151, R21HL150032, P30CA046934, R35GM124939 and RM1GM131968, as well as grants from the Boettcher Foundation and Fast Grants. Additional support was received from Chancellor Discovery Innovation Fund at the CU Anschutz Medical Campus, the Global Down Syndrome Foundation, the Anna and John J. Sie Foundation, and Lyda Hill Philanthropies. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research participants were recruited and consented for participation in the COVID Biobank of the University of Colorado Anschutz Medical Campus [Colorado Multiple Institutional Review Board (COMIRB) Protocol # 20-0685]. Data was generated from deidentified biospecimens and linked to demographics and clinical metadata procured through the Health Data Compass at the University of Colorado under COMIRB Protocol # 20-1700.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated for this manuscript is made available through the online researcher gateway of the COVIDome Project, known as the COVIDome Explorer, which can be accessed at covidome.org. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD022817. The mass cytometry data has been deposited in Flow Repository under the link: https://flowrepository.org/id/RvFrPyf61bmFlccxkki30pKSU83yWnVEky943X4winAnC7xDP1b7Lu0G36zhv3Qh. The SOMAscan Proteomics, MSD Cytokine Profiles, and Sample Metadata files have been deposited in Mendeley under entry doi:10.17632/2mc6rrc5j3.1. https://medschool.cuanschutz.edu/covidome/